new-recommended-broker-banner new-recommended-broker-banner

AstraZeneca Share Price: Japan Approves Imfinzi Drug

Updated: 21 Aug 2020

Shares of Astrazeneca PLC (LON: AZN) slipped around 1% on Friday despite the approval that its Imfinzi drug received from the regulators in Japan. 

Imfinzi, the immunotherapy treatment, is one of the best-selling drugs produced by the pharma giant, having generated $954 million in the first half of the year. 

“This approval of Imfinzi provides an important new immunotherapy option in Japan for patients with extensive-stage small cell lung cancer,” Dave Fredrickson, AstraZeneca'’s executive VP for oncology said.

new-recommended-broker-banner

“These patients have an especially poor prognosis, with only two per cent surviving beyond five years. Imfinzi, in combination with chemotherapy, delivers a sustained survival benefit and prolonged treatment response with a convenient dosing regimen given every four weeks during maintenance.”

AstraZeneca share price slips despite a new approval for its treatment August 2020

Results from trials show that Imfinzi and chemotherapy treatment decreased the risk of death by 27% when compared with the chemotherapy treatment alone.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .